|
Search
Collections
Benchmarks
Upload document
Product
CAL-101
Rename entity
Add alias
Merge entity
Delete entity
Embed entity
1 clinical trial
1 indication
Indication
Chronic lymphocytic leukemia
Clinical trial
Prospective, Open-label, Multicenter Phase-II Trial to Evaluate Efficacy and Safety of a Sequential Regimen of Bendamustine Followed by GA101 (Obinutuzumab) and CAL-101 (Idelalisib) Followed by CAL-101 and GA101 Maintenance in CLL Patients
Status: Completed
, Estimated PCD: 2022-03-09